The State issued guidelines for the development of the pharmaceutical industry during the "Eleventh Five-Year Plan" period
2018-05-25 00:59:47
The “Eleventh Five-Year Development Guidance Opinions for the Pharmaceutical Industry†developed and researched by the National Development and Reform Commission was formally promulgated and implemented in recent days. Zhang Guobao, deputy director of the National Development and Reform Commission, said on the 31st that this move was aimed at guiding the establishment of a pharmaceutical industry with strong international competitiveness, and promoting the entry of some fields into the world's leading ranks, laying a solid foundation for the transition to a powerful pharmaceutical country.
The “Eleventh Five-Year Development Guidance Opinions for the Pharmaceutical Industry†put forward the main development goals of the Chinese pharmaceutical industry from 2006 to 2010:
——In the field of chemical raw material medicine, realize the industrialization of 20 products with high market growth potential and high added value;
- In the field of chemical drug preparations, strive to obtain the listing qualification of 5 pharmaceutical products in the United States or EU countries;
——In the field of traditional Chinese medicine products, develop and market 20 to 30 modern Chinese medicine products with perfect quality standards, clear mechanism of efficacy, safety, efficiency, stability, and controllability;
- In the areas of major, acute infectious diseases and chronic severe diseases, strive to achieve the industrialization of 10 to 15 innovative drugs and new vaccines with Chinese independent intellectual property rights;
——In the field of medical device products, 10 to 20 new types of digital, non-invasive or minimally invasive diagnostic and therapeutic equipment and medical materials have been industrialized.
“In the future, China will pay more attention to improving the independent innovation capability of pharmaceutical companies and strengthening the research and development of innovative drugs. According to Zhang Guobao, the current lack of investment in R&D by Chinese pharmaceutical companies and their weak innovation capacity have become the key to the in-depth development of this industry. problem.
According to the “Eleventh Five-Year Development Guidance Opinions for the Pharmaceutical Industry†and during the “Eleventh Five-Year Plan†period, the R&D investment of Chinese medical devices and key pharmaceutical companies will account for more than 5% of the sales revenue. The R&D investment of pharmaceutical industry companies will reach sales revenue. 3%; Innovative drug research and development will focus on anti-tumor, cardiovascular and cerebrovascular systems, anti-viral infection, neuropsychiatric system, hypoglycemic, geriatric diseases and other fields.
In addition, in the next five years, the country will also cultivate five large-scale pharmaceutical groups with sales of over 5 billion yuan, 10 pharmaceutical commercial enterprises with sales of more than 3 billion yuan, and strive for the initial development of five or so local companies. International pharmaceutical companies.
Zhang Guobao said that the guidance is not mandatory. The purpose of formulating this guidance is mainly to release information and provide suggestions for pharmaceutical companies, guide the healthy and orderly development of the pharmaceutical industry, and promote economic and social progress.
The “Eleventh Five-Year Development Guidance Opinions for the Pharmaceutical Industry†put forward the main development goals of the Chinese pharmaceutical industry from 2006 to 2010:
——In the field of chemical raw material medicine, realize the industrialization of 20 products with high market growth potential and high added value;
- In the field of chemical drug preparations, strive to obtain the listing qualification of 5 pharmaceutical products in the United States or EU countries;
——In the field of traditional Chinese medicine products, develop and market 20 to 30 modern Chinese medicine products with perfect quality standards, clear mechanism of efficacy, safety, efficiency, stability, and controllability;
- In the areas of major, acute infectious diseases and chronic severe diseases, strive to achieve the industrialization of 10 to 15 innovative drugs and new vaccines with Chinese independent intellectual property rights;
——In the field of medical device products, 10 to 20 new types of digital, non-invasive or minimally invasive diagnostic and therapeutic equipment and medical materials have been industrialized.
“In the future, China will pay more attention to improving the independent innovation capability of pharmaceutical companies and strengthening the research and development of innovative drugs. According to Zhang Guobao, the current lack of investment in R&D by Chinese pharmaceutical companies and their weak innovation capacity have become the key to the in-depth development of this industry. problem.
According to the “Eleventh Five-Year Development Guidance Opinions for the Pharmaceutical Industry†and during the “Eleventh Five-Year Plan†period, the R&D investment of Chinese medical devices and key pharmaceutical companies will account for more than 5% of the sales revenue. The R&D investment of pharmaceutical industry companies will reach sales revenue. 3%; Innovative drug research and development will focus on anti-tumor, cardiovascular and cerebrovascular systems, anti-viral infection, neuropsychiatric system, hypoglycemic, geriatric diseases and other fields.
In addition, in the next five years, the country will also cultivate five large-scale pharmaceutical groups with sales of over 5 billion yuan, 10 pharmaceutical commercial enterprises with sales of more than 3 billion yuan, and strive for the initial development of five or so local companies. International pharmaceutical companies.
Zhang Guobao said that the guidance is not mandatory. The purpose of formulating this guidance is mainly to release information and provide suggestions for pharmaceutical companies, guide the healthy and orderly development of the pharmaceutical industry, and promote economic and social progress.